ADMA Biologics, Inc. (ADMA)
- Previous Close
21.20 - Open
20.72 - Bid 19.91 x 500
- Ask 20.08 x 300
- Day's Range
19.86 - 21.48 - 52 Week Range
7.96 - 25.67 - Volume
4,103,666 - Avg. Volume
3,498,901 - Market Cap (intraday)
4.77B - Beta (5Y Monthly) 0.57
- PE Ratio (TTM)
23.79 - EPS (TTM)
0.84 - Earnings Date Aug 6, 2025 - Aug 11, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
29.49
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
www.admabiologics.comRecent News: ADMA
View More
Performance Overview: ADMA
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ADMA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ADMA
View MoreValuation Measures
Market Cap
5.06B
Enterprise Value
5.07B
Trailing P/E
25.24
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
11.33
Price/Book (mrq)
13.55
Enterprise Value/Revenue
11.04
Enterprise Value/EBITDA
33.12
Financial Highlights
Profitability and Income Statement
Profit Margin
46.35%
Return on Assets (ttm)
21.24%
Return on Equity (ttm)
81.64%
Revenue (ttm)
426.45M
Net Income Avi to Common (ttm)
197.67M
Diluted EPS (ttm)
0.84
Balance Sheet and Cash Flow
Total Cash (mrq)
103.15M
Total Debt/Equity (mrq)
23.53%
Levered Free Cash Flow (ttm)
75.16M
Research Analysis: ADMA
View MoreResearch Reports: ADMA
View MoreRating decreased to a HOLD
ADMA BIOLOGICS INC has an Investment Rating of HOLD; a target price of $24.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetRaising target price to $28.00
ADMA BIOLOGICS INC has an Investment Rating of BUY; a target price of $28.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetLowering target price to $26.00
ADMA BIOLOGICS INC has an Investment Rating of BUY; a target price of $26.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetRaising target price to $27.00
ADMA BIOLOGICS INC has an Investment Rating of BUY; a target price of $27.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice Target